Access to high quality vaccines

Access to affordable vaccines of assured quality is central to the performance of immunization programmes. A positive enabling environment for vaccine development requires longer-term strategies, significant investment and well-functioning national regulatory agencies and advisory bodies. Networking and information exchange among national regulatory authorities (NRA) results in effective standardization, alignment and compatibility of normative and regulatory processes. Investment in research, development and manufacturing techniques identifies best ways to access appropriate technology and expertise, to manage intellectual property rights and to develop thermostable and suitable products as well as new bioprocessing and manufacturing technologies.